Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also ...

Otsuka subsidiary Taiho Pharmaceuticals earlier announced that the results of a Phase III, randomized, placebo-controlled, ...

French biotech Nanobiotix’ (shares were up nearly 7% at 4.44 euros in early trading, after the company announced two important developments that aim to reinforce the global positioning of potential ...

Shares of US clinical-stage biotech Apogee Therapeutics closed down 17.3% at $39.24 yesterday, despite announcing positive 16 ...

Eli Lilly (NYSE: LLY) led the way in pharma M&A during June. The US pharma major announced two major deals in the month, both ...

Japanese drugmaker Chugai Pharmaceutical has entered into a joint research and license agreement to develop novel therapies for age-related diseases with Singapore-based biotech Gero.

The GPRC5D-directed therapies market is witnessing robust growth, driven by high unmet need in relapsed/refractory multiple ...

Actinogen Medical (ASX: ACW), an Australian biotech, announced that the 100th participant in its pivotal XanaMIA Phase ...

USA and UK-based KalVista Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Ekterly (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of ...

Japan’s Nxera Pharma is to receive a $4.8 million milestone payment from UK pharma company Centessa Pharmaceuticals as part of the firms’ research collaboration.

A nasal COVID-19 vaccine developed by US biotech CyanVac has produced encouraging results in an early trial, showing potential to offer broader immunity and easier delivery than current injections.

The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK ...